Camurus
ISIN: SE0007692850 | Ticker: CAMX | LEI: 5493003S6Z6VI7WYFQ06
Country: Sweden
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions.
New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of opioid dependence and chronic pain, rare diseases, oncology and supportive care, which are developed in-house and in collaboration with international pharmaceutical companies.
1991
HeadquartersIdeongatan 1A, 22362 Lund – Sweden
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 1,044,098,000.00 | 1,081,897,000.00 | 1,305,488,000.00 |
| Noncurrent Assets | N/A | 375,612,000.00 | 402,595,000.00 | 390,143,000.00 |
| Fixtures And Fittings | N/A | 8,805,000.00 | 9,882,000.00 | 9,270,000.00 |
| Intangible Assets Under Development | N/A | 36,597,000.00 | 33,713,000.00 | 23,597,000.00 |
| Noncurrent Receivables | N/A | N/A | 0.00 | 6,997,000.00 |
| Deferred Tax Assets | N/A | 305,116,000.00 | 334,153,000.00 | 324,667,000.00 |
| Current Assets | N/A | 668,486,000.00 | 679,302,000.00 | 915,345,000.00 |
| Inventories | N/A | 111,349,000.00 | 107,202,000.00 | 107,431,000.00 |
| Current Trade Receivables | N/A | 52,191,000.00 | 135,994,000.00 | 196,863,000.00 |
| Other Current Receivables | N/A | 35,490,000.00 | 17,887,000.00 | 21,782,000.00 |
| Cash and cash equivalents | 358,744,000.00 | 461,793,000.00 | 411,575,000.00 | 565,539,000.00 |
| Equity And Liabilities | N/A | 1,044,098,000.00 | 1,081,897,000.00 | 1,305,488,000.00 |
| Issued Capital | N/A | 1,356,000.00 | 1,371,000.00 | 1,386,000.00 |
| Retained Earnings | N/A | -950,999,000.00 | -1,039,858,000.00 | -980,448,000.00 |
| Additional Paidin Capital | N/A | 1,797,084,000.00 | 1,887,395,000.00 | 1,973,733,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 847,441,000.00 | 848,908,000.00 | 994,671,000.00 |
| Noncurrent Liabilities | N/A | 20,387,000.00 | 19,944,000.00 | 29,175,000.00 |
| Noncurrent Payables On Social Security And Taxes Other Than Income Tax | N/A | N/A | 1,019,000.00 | 12,532,000.00 |
| Current Liabilities | N/A | 176,270,000.00 | 213,045,000.00 | 281,642,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 20,712,000.00 | 52,857,000.00 | 85,548,000.00 |
| Current Accruals And Current Deferred Income Including Current Contract Liabilities | N/A | N/A | 125,561,000.00 | 151,805,000.00 |
| Current Tax Liabilities Current | N/A | 2,839,000.00 | 6,936,000.00 | 9,018,000.00 |
| Line item in (sek) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 335,997,000.00 | 600,570,000.00 | 956,340,000.00 |
| Profit Loss From Operating Activities | -205,232,000.00 | -110,574,000.00 | 71,956,000.00 |
| Finance Income | 194,000.00 | 171,000.00 | 2,695,000.00 |
| Finance Costs | 1,541,000.00 | 1,365,000.00 | 1,526,000.00 |
| Profit Loss Before Tax | -206,579,000.00 | -111,768,000.00 | 73,125,000.00 |
| Income Tax Expense Continuing Operations | -39,314,000.00 | -21,322,000.00 | 17,572,000.00 |
| Profit (loss) | -167,265,000.00 | -90,446,000.00 | 55,553,000.00 |
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -167,265,000.00 | -90,446,000.00 | 55,553,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | -78,257,000.00 | 4,147,000.00 | 374,000.00 |
| Adjustments For Decrease Increase In Other Operating Receivables | N/A | -2,663,000.00 | -8,805,000.00 | -19,200,000.00 |
| Adjustments For Increase Decrease In Trade Account Payable | N/A | 3,325,000.00 | 32,145,000.00 | 32,118,000.00 |
| Adjustments For Increase Decrease In Other Operating Payables | N/A | 54,771,000.00 | 2,993,000.00 | 27,566,000.00 |
| Adjustments For Depreciation And Amortisation Expense | N/A | 11,551,000.00 | 25,204,000.00 | 52,248,000.00 |
| Adjustments For Sharebased Payments | N/A | N/A | 12,500,000.00 | N/A |
| Interest Paid Classified As Operating Activities | N/A | 1,541,000.00 | 1,365,000.00 | 1,526,000.00 |
| Interest Received Classified As Operating Activities | N/A | 194,000.00 | 171,000.00 | 2,695,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -238,832,000.00 | -143,427,000.00 | 101,199,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 968,000.00 | 3,991,000.00 | 1,905,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 2,358,000.00 | 952,000.00 | -7,287,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -3,326,000.00 | -4,943,000.00 | 5,382,000.00 |
| Proceeds From Issuing Other Equity Instruments | N/A | 8,761,000.00 | 243,000.00 | 0.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 4,782,000.00 | 7,142,000.00 | 7,786,000.00 |
| Other Inflows Outflows Of Cash Classified As Financing Activities | N/A | N/A | 0.00 | -7,001,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 347,852,000.00 | 98,904,000.00 | 43,705,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | 105,694,000.00 | -49,466,000.00 | 150,286,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -2,645,000.00 | -752,000.00 | 3,678,000.00 |
| Cash and cash equivalents | 358,744,000.00 | 461,793,000.00 | 411,575,000.00 | 565,539,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 15.12.23 | Annette Mattsson | Other | Other | SEK 169,500.00 |
| 18.09.23 | Annette Mattsson | Other | Sell | SEK 294,600.00 |
| 06.09.23 | Maria Lundqvist | Other | Other | SEK 0.00 |
| 23.08.23 | Maria Lundqvist | Other | Sell | SEK 22,610.28 |
| 23.08.23 | Maria Lundqvist | Other | Sell | SEK 17,032.86 |
| 23.08.23 | Maria Lundqvist | Other | Other | SEK 13,051.50 |
| 23.08.23 | Maria Lundqvist | Other | Sell | SEK 2,932.60 |
| 23.08.23 | Maria Lundqvist | Other | Other | SEK 1,695.00 |
| 23.08.23 | Maria Lundqvist | Other | Sell | SEK 1,468.60 |
| 23.08.23 | Maria Lundqvist | Other | Other | SEK 847.50 |
SE0007692850
LEI5493003S6Z6VI7WYFQ06
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.